Altamira Medica, an associate company of Altamira Therapeutics, announced that its preservative-free, drug-free Bentrio nasal spray for allergic rhinitis was tested successfully for the absence of more than 230 prohibited substances listed by the World Anti-Doping Agency, WADA. This finding further confirms Bentrio’s suitability for athletes who must comply with antidoping regulations but at the same time need to protect themselves against airborne allergens or other particles.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTO:
- Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
- Altamira Therapeutics announces publication of article on Zbtb46 mRNA
- Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
- Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
- Altamira Therapeutics announces publication of preclinical data on SOD2 mRNA